IDENTIFICATION DETAILS
|
Name : |
LEE PHARMA LIMITED |
|
|
|
|
Country : |
India |
|
|
|
|
Financials (as
on) : |
31.03.2013 |
|
|
|
|
PAN No.: [Permanent Account No.] |
AAACL3435F |
|
|
|
|
Legal Form : |
A Closely Held Public Limited Liability Company |
|
|
|
|
No. of Employees
: |
Information declined by the management |
BUSINESS DETAILS
|
Line of Business : |
Manufacturer of
Active Pharmaceutical Ingredients (APIs) and Bulk Drugs. |
||||||||||||||||||||||
|
|
|
||||||||||||||||||||||
|
Products : |
|
GENERAL INFORMATION
|
No. of Employees : |
Information declined by the management |
|||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
|
Bankers : |
State Bank of India, Industrial Finance Branch, Raj Bhavan
Road, Somajiguda, Hyderabad - 500082, Andhra Pradesh, India |
|||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
|
Facilities : |
|
|
|
|
|
Banking
Relations : |
|
|
|
|
|
Financial Institutions : |
Reliance Capital Limited, "H" Block 1st Floor, Dhirubhai
Ambani Knowledge City, Koparkhairne, Navi Mumbai - 400710, Maharashtra, India |
|
|
|
|
Auditors : |
|
|
Name : |
M. V. Narayana
Reddy and Company Chartered
Accountants |
|
Address : |
Flat No. 504, Vijayasree
Apartments, Behind Chermas, Ameerpet, Hyderabad - 500073, Andhra Pradesh,
India |
|
Tel. No.: |
91-40-23744448 / 23743975 |
|
PAN No.: |
AADFM4830F |
|
|
|
|
Associates: |
CIN: U45201AP2007PTC056353
|
MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN
As on 28.09.2013
|
Names of Shareholders |
|
No. of Shares |
|
Alla Venkata Reddy |
|
249000 |
|
Alla Ratna Kumari |
|
161700 |
|
Alla Raghumitra |
|
102300 |
|
Alla Leela Rani |
|
62100 |
|
P. V. Subba Reddy |
|
16200 |
|
P. Jagadeeshwara Reddy |
|
4050 |
|
P. Padmalatha Reddy |
|
5400 |
|
P. Anjusha Reddy |
|
1350 |
|
P. Venkata Reddy |
|
6750 |
|
P. Varalakshmi |
|
1350 |
|
P. Venkata Reddy |
|
2700 |
|
K. Lahiri |
|
100 |
|
K. Swapna Lahiri |
|
100 |
|
M. Lakshmi Prasanna |
|
100 |
|
P. Madhusudhan Reddy |
|
5400 |
|
P. Bhuvana Reddy |
|
5400 |
|
A. Nagi Reddy |
|
42700 |
|
A. Anjamma Reddy |
|
40800 |
|
K. Tarun Reddy |
|
10000 |
|
K. Bhargav Reddy |
|
10000 |
|
B. Pitchi Reddy |
|
20000 |
|
B. Dhanalakshmi Reddy |
|
15000 |
|
B. Anasurya Reddy |
|
15000 |
|
S. Madhusudhan Reddy |
|
20000 |
|
M. Mallikarjun Rao |
|
100 |
|
A. Vijaya Kumari |
|
100 |
|
B. Rama Subba Reddy |
|
100 |
|
K. Mallikarhun Reddy |
|
100 |
|
T. Gopal Rao |
|
100 |
|
Moehs Iberica S L |
|
616636 |
|
Vijay Kumar Raghunandan Prasad Agarwal |
|
36273 |
|
Total
|
|
1450909 |
FINANCIAL DATA
[all figures are
in Rupees Millions]
|
SOURCES OF FUNDS |
31.03.2013 |
31.03.2012 |
31.03.2011 |
|
I.
EQUITY
AND LIABILITIES |
|
|
|
|
(1)Shareholders' Funds |
|
|
|
|
(a) Share Capital |
14.509 |
14.509 |
14.509 |
|
(b) Reserves & Surplus |
440.269 |
385.440 |
366.669 |
|
(c) Money
received against share warrants |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
(2) Share Application money pending allotment |
0.000 |
0.000 |
0.000 |
|
Total
Shareholders’ Funds (1) + (2) |
454.778 |
399.949 |
381.178 |
|
|
|
|
|
|
(3)
Non-Current Liabilities |
|
|
|
|
(a) long-term borrowings |
99.084 |
41.514 |
53.531 |
|
(b) Deferred tax liabilities (Net) |
41.547 |
37.411 |
33.137 |
|
(c) Other long term
liabilities |
0.000 |
0.000 |
0.000 |
|
(d) long-term
provisions |
5.288 |
5.656 |
6.058 |
|
Total Non-current
Liabilities (3) |
145.919 |
84.581 |
92.726 |
|
|
|
|
|
|
(4) Current Liabilities |
|
|
|
|
(a) Short term
borrowings |
381.802 |
300.400 |
224.370 |
|
(b) Trade payables |
482.840 |
335.636 |
207.981 |
|
(c) Other current
liabilities |
117.432 |
81.903 |
71.714 |
|
(d) Short-term
provisions |
12.901 |
7.511 |
5.717 |
|
Total Current
Liabilities (4) |
994.975 |
725.450 |
509.782 |
|
|
|
|
|
|
TOTAL |
1595.672 |
1209.980 |
983.686 |
|
|
|
|
|
|
II. ASSETS |
|
|
|
|
(1) Non-current assets |
|
|
|
|
(a) Fixed Assets |
|
|
|
|
(i) Tangible assets |
539.064 |
485.247 |
464.124 |
|
(ii) Intangible Assets |
1.755 |
1.019 |
0.000 |
|
(iii) Capital
work-in-progress |
0.000 |
0.000 |
0.000 |
|
(iv)
Intangible assets under development |
0.000 |
0.000 |
0.000 |
|
(b) Non-current Investments |
0.000 |
0.000 |
0.000 |
|
(c) Deferred tax assets (net) |
0.000 |
0.000 |
0.000 |
|
(d) Long-term Loan and Advances |
8.215 |
6.903 |
5.024 |
|
(e) Other Non-current
assets |
0.000 |
0.000 |
0.000 |
|
Total Non-Current
Assets |
549.034 |
493.169 |
469.148 |
|
|
|
|
|
|
(2) Current assets |
|
|
|
|
(a) Current investments |
0.000 |
0.000 |
10.000 |
|
(b) Inventories |
428.021 |
282.117 |
241.543 |
|
(c) Trade receivables |
495.092 |
352.475 |
216.949 |
|
(d) Cash and cash
equivalents |
18.916 |
12.532 |
11.117 |
|
(e) Short-term loans
and advances |
84.316 |
69.582 |
34.112 |
|
(f) Other current
assets |
20.293 |
0.105 |
0.817 |
|
Total Current Assets |
1046.638 |
716.811 |
514.538 |
|
|
|
|
|
|
TOTAL |
1595.672 |
1209.980 |
983.686 |
PROFIT & LOSS
ACCOUNT
|
|
PARTICULARS |
31.03.2013 |
31.03.2012 |
31.03.2011 |
|
|
|
SALES |
|
|
|
|
|
|
|
Income |
1604.710 |
1183.568 |
847.250 |
|
|
|
Other Income |
17.789 |
23.623 |
5.443 |
|
|
|
TOTAL (A) |
1622.499 |
1207.191 |
852.693 |
|
|
|
|
|
|
|
|
Less |
EXPENSES |
|
|
|
|
|
|
|
Cost of materials consumed |
1171.472 |
813.569 |
546.936 |
|
|
|
Purchases of stock-in-trade |
3.884 |
3.056 |
2.810 |
|
|
|
Changes in inventories of finished goods, work-in-progress and stock-in-trade |
(62.686) |
(4.029) |
(19.889) |
|
|
|
Employee benefit expense |
77.685 |
64.453 |
54.505 |
|
|
|
Other expenses |
304.444 |
234.340 |
195.036 |
|
|
|
TOTAL (B) |
1494.799 |
1111.389 |
779.398 |
|
|
|
|
|
|
|
|
Less |
PROFIT
BEFORE INTEREST, TAX, DEPRECIATION AND AMORTISATION (A-B) (C) |
127.700 |
95.802 |
73.295 |
|
|
|
|
|
|
|
|
|
Less |
FINANCIAL
EXPENSES (D) |
46.034 |
37.675 |
26.211 |
|
|
|
|
|
|
|
|
|
|
PROFIT
BEFORE TAX, DEPRECIATION AND AMORTISATION (C-D) (E) |
81.666 |
58.127 |
47.084 |
|
|
|
|
|
|
|
|
|
Less/ Add |
DEPRECIATION/
AMORTISATION (F) |
32.126 |
28.687 |
24.740 |
|
|
|
|
|
|
|
|
|
|
PROFIT BEFORE
TAX (E-F) (G) |
49.540 |
29.440 |
22.344 |
|
|
|
|
|
|
|
|
|
Less |
TAX (H) |
8.258 |
10.669 |
9.279 |
|
|
|
|
|
|
|
|
|
|
PROFIT AFTER TAX
(G-H) (I) |
41.282 |
18.771 |
13.065 |
|
|
|
|
|
|
|
|
|
Add |
PREVIOUS
YEARS’ BALANCE BROUGHT FORWARD |
52.458 |
43.687 |
40.622 |
|
|
|
|
|
|
|
|
|
Add |
MAT CREDIT
ENTITLEMENT |
11.546 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
|
Less |
APPROPRIATIONS |
|
|
|
|
|
|
|
Transfer to General Reserve |
10.000 |
10.000 |
10.000 |
|
|
BALANCE CARRIED
TO THE B/S |
95.287 |
52.458 |
43.687 |
|
|
|
|
|
|
|
|
|
|
Earnings Per
Share (Rs.) |
28.45 |
12.94 |
9.00 |
|
REVIEW OF THE BUSINESS OPERATIONS
During the year,
the Company has clocked a Total Income of Rs.1622.499 Millions as against Rs.1207.191
Millions in the preceding financial year registering a growth of 34.59 % in the
current year sales. The company has earned a net profit of Rs.41.283 Millions
(previous year Rs.18.771 Millions) after providing for taxes of Rs.14.730 Millions
(previous year Rs.10.669 Millions).
During the year
the company has strengthed its position in both the export and domestic market.
In the export market for US, the company has filed its first USDMF for
Lansoprazole and anti ulcerative product having a market of more than One US
billion. In the coming financial year the company will be able to add 3 to 4
USDMF. In the european market, the company has got CEP approval for
Lansoprazole basing on which it will be able to increase its sales for the
coming financial year.
The company is
also now holding a strong share in domestic market for APIS. This is because
the company has been able to get into new segment molecules like Montelukast
Sodium, Atorvastatin Calcium, Rosuvastatin Calcium and Moxifloxacin. Company is
major supplier to all the big formulation gaints in Indian Market. Its expecting
to improve more in the coming financial year.
The Directors
assure you that they will make every effort and do not leave any stone unturned
to stand up and be counted as one of the pharma giants of the country.
RATING & COMMENTS
|
MIRA’s Rating : |
Ba (49) |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
Usually correct |
|
|
|
|
Litigation : |
Clear |
RBI DEFAILTERS’ LIST STATUS
Subject’s name is not enlisted as a defaulter
in the publicly available RBI Defaulters’ list.
LOCATIONS
|
Registered Office : |
Survey No. 257 and 258/1, Door No. 11-6/56, C Block, Opposite IDPL
Factory, Moosapet (Village), Balanagar (Post), Hyderabad 500037, Andhra
Pradesh, India |
|
Tel. No.: |
91-40-66170334 / 66170336 |
|
Fax No.: |
91-40-66170330 |
|
E-Mail : |
|
|
Website : |
|
|
|
|
|
Factory : |
Located At
|
|
|
|
|
Research Centre : |
Located At
|
NOTE:
The registered office of the company has been shifted from Flat
No: 401, A - Block, Saidatta Apartments,
Srinivasa Nagar Colony (East), Ameerpet, Hyderabad – 500038, Andhra Pradesh, India to present
address w.e.f. 09.05.2007
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.